14 maj: Audi sætter nye rekorder
17 maj: IWC Portuguese Yachtclub Volvo Ocean Race
15-05-2012 07:59:59

Interim Report for FLSmidth & Co. A/S 1 January - 31 March 2012

Relateret indhold
16 jan - 
Tirsdagens aktier: Pandora begejstrede på kapitalmarked..
16 jan - 
Aktier/middag: Pandora overstråler alt i nølende elitei..
15 jan - 
Mandagens aktier: FLSmidth i bund efter skidt nyt fra f..
Relateret debat
16 jan - 
sjovr metso og out rebounder idag, men fls er nærmest h..
10 jan - 
Patenter mangler! FLS skal konkurrere med lande som giv..
10 jan - 
Skønt at FL.S ikke er bundet op på stor ordrebeholdning..

Company Announcement to the Danish Financial Supervisory Authority No. 24-2012, 15 May 2012

The Board of Directors and the Group Management of FLSmidth & Co. A/S have today reviewed and adopted the Interim Report for the period 1 January to 31 March 2012.

The Interim Report is presented in accordance with IAS 34, presentation of Interim Reports, as approved by the EU, and additional Danish disclosure requirements for interim reports submitted by listed companies.

The Interim Report has not been audited nor reviewed by the Group auditor.

The Interim Report is accessible at FLSmidth's website:

http://www.flsmidth.com/reports

The main conclusions of the Interim Report are:

Outlook for 2012 (unchanged at Group level)

In 2012, FLSmidth & Co. A/S still expects consolidated revenue of DKK 24-26bn exclusive of acquisitions (2011: DKK 22bn), an EBITA margin of minimum 10% (2011: 10.9%) and an EBIT margin of 9-10% (2011: 9.9%).

The effect of purchase price allocations (exclusive of new acquisitions) is expected to be around DKK 220m in 2012 (2011: DKK 178m).

Cash flow from investing activities (exclusive of acquisitions) is expected to be around DKK -900m in 2012 (2011: DKK -733m) due to the investment in eight supercentres and the expansion of activities in India and China.

The effective tax rate is expected to be approximately 30-32% in 2012 (2011: 31%) and tax payable slightly lower.

Financial results in Q1 2012

Strong order intake in Q1 confirms growth expectations and positive outlook

The order intake increased 29% to DKK 6,421m (Q1 2011: DKK 4,964m)

Revenue increased 17% to DKK 5,145m (Q1 2011: DKK 4,385m)

Earnings before interest, tax, depreciation and amortisation (EBITDA) increased 10% to DKK 469m (Q1 2011: DKK 427m), corresponding to an EBITDA margin of 9.1% (Q1 2011: 9.7%)

The order backlog increased 6% in Q1 to DKK 28,736m (end 2011: DKK 27,136m)

Earnings before amortisation and write-down of intangible assets (EBITA) increased 11% to DKK 402m (Q1 2011: DKK 363m), corresponding to an EBITA margin of 7.8% (Q1 2011: 8.3%)

Earnings before interest and tax (EBIT) increased 10% to DKK 334m (Q1 2011: DKK 305m), corresponding to an EBIT margin of 6.5% (Q1 2011: 7.0%)

Earnings before tax (EBT) increased 39% to DKK 346m (Q1 2011: DKK 249m)

The profit for the period increased 39% to DKK 241m (Q1 2011: DKK 174m)

Cash flow from operating activities amounted to DKK -117m (Q1 2011: DKK -101m)

Net interest-bearing debt by the end of Q1 2012 amounted to DKK 386m (end of 2011: DKK 98m)

Please address any questions to this announcement to Mr Jørgen Huno Rasmussen, Group CEO, telephone +45 36 18 18 00.

An investor & press meeting and telephone conference regarding the Interim Report will be held today at 11:00 hours CET at the company's headquarters.

For further details please visit www.flsmidth.com.

FLSmidth & Co. A/S

Corporate Communications & Investor Relations

1st Quarter Report 2012


This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients.

The owner of this announcement warrants that:

(i) the releases contained herein are protected by copyright and other applicable laws; and

(ii) they are solely responsible for the content, accuracy and originality of the

information contained therein.

Source: FLSmidth via Thomson Reuters ONE

HUG#1612204

Opret kommentar

Relateret debat

  • 1 uge
  • 1 måned
  • 1 År
Ingen indlæg

Novo Nordisk/Goldman: Diabetestablet vil få den høje vækst tilbage

19-01-2018 15:11:36
Novo Nordisk står med et meget stærkt kort på hånden, hvis selskabet får en tabletudgave af det store væksthåb Ozempic (Semaglutid) godkendt og sendt på markedet.Det mener den amerikanske investeringsbank Goldman Sachs, der vurderer, at investorerne på aktiemarkedet ikke har taget tilstrækkeligt højde for de store muligheder for diabetesmidlet.Derfor har banken hævet sit kursmål for Novo Nordisk-a..

WDH/SEB: Amerikansk høreapparatmarked vokser mere end ventet

19-01-2018 14:35:39
Der var mere fart på den private del af det amerikanske høreapparatmarked i slutningen af 2017, end den svenske bank SEB havde ventet.Det skriver Bloomberg News på baggrund af en analyse fra SEB.Den private del af det amerikanske høreapparatmarked voksede 7,3 pct. i fjerde kvartal mod 2,8 pct. i tredje kvartal ifølge tal fra American Hearing Aid Association. Det var højere, end SEB har ventet, og ..

Aktier/åbning: Børshuse skubber Chr. Hansen og Novo til tops

19-01-2018 09:23:02
Chr. Hansen og Novo Nordisk er strøget til tops på det danske aktiemarked og medvirker til at hive det danske C25-indeks i et solidt plus fredag morgen.Stemningen var ellers svagt negativ i futuremarkedet indtil kort før åbningen.C25-indekset stiger 0,5 pct. til 1160,09 og ligger til et samlet plus på 0,8 pct. i denne uge.Især Chr. Hansen er sprunget i vejret fra åbningen. Aktien stiger 3,9 pct. t..

Mest læste nyheder

  • 24 timer
  • 48 timer
  • 1 uge

Relaterede aktiekurser

FLSmidth & Co A/S 366,40 0,0% Aktiekurs uændret

Køb- og salgsanbefalinger

  • Trend
  • Pengemaskinen

Copyright Euroinvestor A/S 2018  Disclaimer Privatlivspolitik
Aktieinformation leveres af Morningstar.
Data er forsinket 15-20 minutter iht. de enkelte børsers regler om videredistribution.
 
20. januar 2018 21:28:16
(UTC+01:00) Brussels, Copenhagen, Madrid, Paris
Version: LiveBranchBuild_20180112.1 - EUROWEB1 - 2018-01-20 21:28:16 - 2018-01-20 21:28:16 - 1 - Website: OKAY